Substances that are recognized by the immune system and induce an immune reaction.
Substances elaborated by bacteria that have antigenic activity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Substances elaborated by viruses that have antigenic activity.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Substances of fungal origin that have antigenic activity.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.
The major group of transplantation antigens in the mouse.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
Antibodies produced by a single clone of cells.
A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
Sites on an antigen that interact with specific antibodies.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)
A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Established cell cultures that have the potential to propagate indefinitely.
Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.
One of four subsections of the hippocampus described by Lorente de No, located furthest from the DENTATE GYRUS.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.
A subsection of the hippocampus, described by Lorente de No, that is located between the HIPPOCAMPUS CA2 FIELD and the DENTATE GYRUS.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Cation-transporting proteins that utilize the energy of ATP hydrolysis for the transport of CALCIUM. They differ from CALCIUM CHANNELS which allow calcium to pass through a membrane without the use of energy.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
The sum of the weight of all the atoms in a molecule.
A network of tubules and sacs in the cytoplasm of SKELETAL MUSCLE FIBERS that assist with muscle contraction and relaxation by releasing and storing calcium ions.
Elements of limited time intervals, contributing to particular results or situations.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
Proteins prepared by recombinant DNA technology.
Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.
An encapsulated lymphatic organ through which venous blood filters.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.
Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.
A sesquiterpene lactone found in roots of THAPSIA. It inhibits CA(2+)-TRANSPORTING ATPASE mediated uptake of CALCIUM into SARCOPLASMIC RETICULUM.
The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.
A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents.
A sex-specific cell surface antigen produced by the sex-determining gene of the Y chromosome in mammals. It causes syngeneic grafts from males to females to be rejected and interacts with somatic elements of the embryologic undifferentiated gonad to produce testicular organogenesis.
A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
An electrogenic ion exchange protein that maintains a steady level of calcium by removing an amount of calcium equal to that which enters the cells. It is widely distributed in most excitable membranes, including the brain and heart.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling.
A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research.
Long-lasting voltage-gated CALCIUM CHANNELS found in both excitable and nonexcitable tissue. They are responsible for normal myocardial and vascular smooth muscle contractility. Five subunits (alpha-1, alpha-2, beta, gamma, and delta) make up the L-type channel. The alpha-1 subunit is the binding site for calcium-based antagonists. Dihydropyridine-based calcium antagonists are used as markers for these binding sites.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.
Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
An electrophysiologic technique for studying cells, cell membranes, and occasionally isolated organelles. All patch-clamp methods rely on a very high-resistance seal between a micropipette and a membrane; the seal is usually attained by gentle suction. The four most common variants include on-cell patch, inside-out patch, outside-out patch, and whole-cell clamp. Patch-clamp methods are commonly used to voltage clamp, that is control the voltage across the membrane and measure current flow, but current-clamp methods, in which the current is controlled and the voltage is measured, are also used.
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
Diagnostic procedures involving immunoglobulin reactions.
Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.
A group of dominantly and independently inherited antigens associated with the ABO blood factors. They are glycolipids present in plasma and secretions that may adhere to the erythrocytes. The phenotype Le(b) is the result of the interaction of the Le gene Le(a) with the genes for the ABO blood groups.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
Immunoglobulins produced in a response to HELMINTH ANTIGENS.
The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.
Antigens which may directly stimulate B lymphocytes without the cooperation of T lymphocytes.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.
A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Glycoproteins found on the membrane or surface of cells.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
An increased reactivity to specific antigens mediated not by antibodies but by cells.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
Immunologically detectable substances found in the CELL NUCLEUS.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.
Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.
Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement.
A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*27 allele family.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Antigens produced by various strains of HEPATITIS D VIRUS.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Class I human histocompatibility (HLA) antigens encoded by a small cluster of structural genes at the C locus on chromosome 6. They have significantly lower immunogenicity than the HLA-A and -B determinants and are therefore of minor importance in donor/recipient crossmatching. Their primary role is their high-risk association with certain disease manifestations (e.g., spondylarthritis, psoriasis, multiple myeloma).
Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.
Agents that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags.
A tetrameric calcium release channel in the SARCOPLASMIC RETICULUM membrane of SMOOTH MUSCLE CELLS, acting oppositely to SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES. It is important in skeletal and cardiac excitation-contraction coupling and studied by using RYANODINE. Abnormalities are implicated in CARDIAC ARRHYTHMIAS and MUSCULAR DISEASES.
A major histocompatibily complex class I-like protein that plays a unique role in the presentation of lipid ANTIGENS to NATURAL KILLER T-CELLS.
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*01 allele family.
Polysaccharides found in bacteria and in capsules thereof.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Intracellular receptors that bind to INOSITOL 1,4,5-TRISPHOSPHATE and play an important role in its intracellular signaling. Inositol 1,4,5-trisphosphate receptors are calcium channels that release CALCIUM in response to increased levels of inositol 1,4,5-trisphosphate in the CYTOPLASM.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*07 allele family.
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
An HLA-DR antigen which is associated with HLA-DRB1 CHAINS encoded by DRB1*04 alleles.
A heat-stable, low-molecular-weight activator protein found mainly in the brain and heart. The binding of calcium ions to this protein allows this protein to bind to cyclic nucleotide phosphodiesterases and to adenyl cyclase with subsequent activation. Thereby this protein modulates cyclic AMP and cyclic GMP levels.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
Proteins to which calcium ions are bound. They can act as transport proteins, regulator proteins, or activator proteins. They typically contain EF HAND MOTIFS.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Tumors or cancer of the PROSTATE.
An HLA-DR antigen which is associated with HLA-DRB1 CHAINS encoded by DRB1*03 alleles.
Tests that are dependent on the clumping of cells, microorganisms, or particles when mixed with specific antiserum. (From Stedman, 26th ed)
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Proteins found in any species of bacterium.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
The rate dynamics in chemical or physical systems.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
A member of the tumor necrosis factor receptor superfamily found on most T-LYMPHOCYTES. Activation of the receptor by CD70 ANTIGEN results in the increased proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*24 allele family.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

Increased serum CA 19-9 antibodies in Sjogren's syndrome. (1/328)

A 67-year-old woman with a history of thyroiditis presented with recent intermittent epigastric pain and nausea. Hyperamylasaemia, oedema of the pancreas, and high serum levels of lipase and CA 19-9 were found. Xerostomia and dry eyes developed later, accompanied by an abnormal Schirmer's test. The diagnosis of Sjogren's syndrome was confirmed by increased anti-Ro and anti-La antibodies and the histological findings of parotid gland biopsy. Two additional cases of Sjogren's syndrome with elevated serum CA 19-9 are also described. These observations of elevated serum lipase and serum CA 19-9 in Sjogren's syndrome without evidence of malignancy may reflect pancreatic involvement in this disorder.  (+info)

Time-resolved immunofluorometric assay of trypsin-1 complexed with alpha(1)-antitrypsin in serum: increased immunoreactivity in patients with biliary tract cancer. (2/328)

BACKGROUND: Increased serum concentrations of trypsin immunoreactivity occur in patients with biliary tract cancer. To characterize this trypsin, we developed a sensitive time-resolved immunofluorometric assay for trypsin-1 complexed with alpha(1)-antitrypsin (AAT) and studied the concentrations of this complex in sera from healthy individuals (n = 130) and patients with benign biliary disease (n = 32), biliary tract cancer (n = 17), pancreatic cancer (n = 27), and hepatocellular cancer (n = 12). METHODS: We used a trypsin-1-specific monoclonal antibody on the solid phase and a europium-labeled polyclonal antibody to AAT as tracer. The detection limit was 0.42 microgram/L. The validity of the trypsin-1-AAT test for detection of biliary tract cancer was compared with trypsin-2-AAT and CA19-9. RESULTS: Increased concentrations of trypsin-1-AAT (>33 microgram/L) were found in 76% of patients with biliary tract cancer, and the concentrations were significantly higher than in those with benign biliary disease (P <0. 0001). The median concentration of trypsin-1-AAT in serum from patients with biliary tract cancer was 3.7-fold higher than in healthy controls, 2.6-fold higher than in patients with benign biliary tract disease, 1.7-fold higher than in patients with pancreatic cancer, and 2.0-fold higher than in patients with hepatocellular cancer. CONCLUSIONS: Of the markers studied, trypsin-1-AAT had the largest area (0.83) under the receiver operating curve in differentiating biliary tract cancer from benign biliary tract disease. Our results suggest that trypsin-1-AAT is a new potential marker for biliary tract cancer.  (+info)

Detection of large molecular weight cytokeratin 8 as carrier protein of CA19-9 in non-small-cell lung cancer cell lines. (3/328)

It has been reported that cytokeratin 8 (CK8) is expressed in all non-small-cell lung cancers (NSCLC). We hypothesized that antigenic changes of CK8 may occur in some NSCLC cell lines. To prove this, Western immunoblot analysis using anti-human CK8 monoclonal antibodies as well as immunohistological staining of CK8 were performed in NSCLC cell lines. As a result, CK8 which had a higher molecular weight than recombinant CK8 was demonstrated in two of eight NSCLC cell lines. In addition, this CK8 contained antigenic epitopes of CA19-9. This CK8 with higher molecular weight, may have played a role in the process of invasion or metastasis of NSCLC.  (+info)

Giant hydronephrosis due to a ureteral stone, and elevated serum levels of CA 19-9. (4/328)

CA 19-9 is a widely used tumor marker. However, an elevation in serum CA 19-9 can occur in some patients with benign disorders such as cholecystolithiasis in the absence of tumor. We treated a case of acquired ureteral stone-induced giant hydronephrosis with markedly elevated serum CA 19-9 values. After nephrectomy, the serum CA 19-9 level returned to normal. No malignant cells were found in the tissues of the resected kidney. Localization of CA 19-9 was confirmed by immunohistochemical staining of the renal pelvic mucosa. A detailed case report is presented with a review of the literature.  (+info)

Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. (5/328)

BACKGROUND: To evaluate whether tumor markers can be used to assess response to systemic chemotherapy, we analyzed preliminarily the relationship between the response to chemotherapy based on serial imaging and on change in serum tumor marker level of CEA, CA19-9 and CA125. METHODS: We analyzed 26 patients with advanced gastric cancer in whom at least one of the tumor markers CEA, CA19-9 and CA125 was elevated before systemic chemotherapy with regard to the relationship between the change in serum tumor marker level and response assessment by imaging studies throughout the treatment course. A responder was defined as showing a > or = 50% drop in tumor marker level for more than 4 weeks. RESULTS: The sensitivity and negative predictive value of falling tumor marker level after chemotherapy for a partial response in imaging was 100%. When patients were categorized as responders or non-responders, a significant correlation was observed between the assessment of response by tumor markers and by imaging studies. The survival time of responders assessed by tumor markers was significantly longer than that of non-responders. CONCLUSIONS: The measurement of tumor markers might be useful in monitoring response and in predicting the prognosis of patients with advanced gastric cancer treated with systemic chemotherapy. Tumor markers may be used as a means of monitoring treatment in patients when in an imaging study it is difficult to assess response to chemotherapy in clinical practice. Further studies are required to confirm these findings.  (+info)

Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women. (6/328)

Information on menstrual cycle dependent variation of tumor markers in healthy women is a subject of diagnostic efficiency and has an impact in elucidating the normal function of these markers. In this study midfollicular and midluteal concentrations of serum CEA, AFP, CA 19-9, CA 125, CA 15-3 and their relations with LH, FSH, prolactin, estradiol and progesterone were evaluated during ovulatory cycles in a group of 23 healthy female individuals. Samples were collected on the 7th and 21st day of the same menstrual cycle. Tumor marker and hormone concentrations were determined with chemiluminescence or electrochemiluminescence EIA methods. A significant phase-dependent difference was observed for CA 15-3, midluteal concentrations (mean +/- SEM; 26.33 +/- 1.56 U/ml) higher than the midfollicular (mean +/- SEM; 19.27 +/- 1.49 U/ml) concentrations (p < 0.001). But an obvious difference for other tumor markers investigated did not exist. Significant correlations of follicular and luteal CA 125 levels with body mass index of the subjects were observed (r:0.52, p < 0.05 and r:0.57, p < 0.005, respectively). CA 15-3 antigen is a product of the MUC-1 gene which is expressed in abundance by endometrial epithelial cells in the secretory phase of the menstrual cycle which may be the potential source of variability. The association of CA 125 levels with obesity suggests a possible role of adipose tissue in CA 125 metabolism. In conclusion our data suggest that in healthy women serum CA 15-3 levels are significantly elevated in the midluteal phase of the menstrual cycle compared to midfollicular phase. Therefore, consideration of menstrual cycle dependent variability for CA 15-3 appears indicated in interpretation of individual results.  (+info)

Establishment and analysis of biological characteristics of a human duodenal carcinoma cell line, WDC-1. (7/328)

BACKGROUND: Duodenal carcinoma is very rare and its culture cell lines have rarely been established. METHODS: Tumor cells separated from a surgically resected primary tumor of duodenal carcinoma were put into culture. The patient was an 81-year-old female and had metastatic lymph nodes. We investigated the biological characteristics of the culture cells including in vitro cell kinetics, karyotype, expression of tumor markers and integrins and tumorigenicity and histology in nude mice. RESULTS: A new cell line, designated WDC-1, was established. This duodenal carcinoma cell line proliferated in a monolayered sheet with a doubling time of 50 h. The histological findings of the xenograft in nude mice were similar to those of the primary tumor. WDC-1 cells produced carcinoembryonic antigen and expressed 1 integrin and very late antigen (VLA)-4d in vitro. CONCLUSIONS: A duodenal carcinoma cell line was established, which is rare and may contribute to progress in understanding the biological features of duodenal cancer.  (+info)

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. (8/328)

Chemotherapy with gemcitabine has been shown to be an effective regimen in advanced or metastatic pancreatic cancer with improvement of both quality of life and survival time. The response of the tumour marker CA 19-9 to chemotherapy with gemcitabine was studied in order to find out whether it is related to survival time of patients. Forty-three consecutive patients (median age 61 years, range 39-76 years; 20 males, 23 females) suffering from histologically proven locally advanced or metastatic pancreatic adenocarcinoma and a baseline Karnofsky-index > or = 60 were treated with gemcitabine in a dose of 1,000 mg/m(-2) weekly x 7 followed by 1 week of rest during the first cycle and thereafter 1,000 mg/m(-2) weekly x 3 followed by 1 week of rest until progression. In 36 of 43 patients serial measurements of CA 19-9 could be performed. Patients with a decrease of > 20% of the baseline CA 19-9 level after 8 weeks of treatment (n = 25) had a significantly better median survival than patients with a rise or a decrease < or = 20% (n = 11) (268 vs 110 days; P < 0.001). The response of CA 19-9 was the strongest independent predictor of survival (P < 0.001) in the multivariate analysis. In conclusion, a decrease of CA 19-9 > 20% during the first weeks of chemotherapy with gemcitabine is associated with a better survival of patients with locally advanced or metastatic pancreatic cancer. Serial measurements of CA 19-9 are useful to decide whether further chemotherapy after the first weeks of treatment is indicated.  (+info)

TY - JOUR. T1 - The combination of neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic indicator in patients with recurrent pancreatic cancer. AU - Sakamoto, Teruhisa. AU - Saito, Hiroaki. AU - Uchinaka, Ei. AU - Morimoto, Masaki. AU - Amisaki, Masataka. AU - Tokuyasu, Naruo. AU - Honjo, Soichiro. AU - Ashida, Keigo. AU - Fujiwara, Yoshiyuki. PY - 2018/9. Y1 - 2018/9. N2 - Background/Aim: We retrospectively investigated the relationship between prognosis and combined neutrophil-to-lymphocyte ratio (NLR) and serum carbohydrate antigen 19-9 (CA19-9) levels in patients with recurrent pancreatic cancer. Patients and Methods: We enrolled 66 patients whose pancreatic cancer recurred. Results: Based on ROC analysis results, the patients were divided into NLRHigh (NLR ≥1.69) or NLRLow (NLR ,1.69), and into CA19-9High (CA19-9 ≥107.95 U/ml) or CA19-9Low (CA19-9 ,107.95 U/ml). When the patients were grouped by combined NLR and CA19-9, their 2-year survival rates ...
Table 1: Elevated Preoperative Serum CA125 Predicts Larger Tumor Diameter in Patients with Hepatocellular Carcinoma and Low AFP Levels
BACKGROUND Papillary-serous adenocarcinoma (PSCC) is a very rare subtype of cervical cancer. To our knowledge, this is the first report on PSCC of the uterine cervix following bilateral breast cancer. CASE REPORT A 61-year-old Caucasian woman underwent conserving surgery of both breasts at the age of 57 years, because of bilateral invasive ductal carcinoma. Radiation and tamoxifen treatment followed. Routine surveillance examinations, including pelvic examination, Papanicolaou (Pap) smear, and transvaginal ultrasound, were uneventful. Recently, a small contact-bleeding mass of the cervix was found. The Pap smear was II (reactive); HPV-DNA test was negative. The biopsy of the mass revealed PSCC with a high expression of p53, carcinoembryonic antigen (CEA), and Ki67 (50%). Staining for estrogen receptor (ER), progesterone receptor (PR), and vimentin was negative. The serum carbohydrate antigen 125 (CA-125) reached 159 U/ml. The patient was treated with radical hysterectomy, bilateral salpingo
Prognostic impact of preoperative tumor marker levels and lymphovascular invasion in pathological stage I adenocarcinoma and squamous cell carcinoma of the lung(要約)Prognostic impact of preoperative tumor marker levels and lymphovascular invasion in pathological stage I adenocarcinoma and squamous cell carcinoma of the lung(要約) ...
PubMed journal article: Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Download Prime PubMed App to iPhone, iPad, or Android
In cases with findings on examination or imaging tests that suggest cancer, measuring blood levels of tumor markers may provide additional evidence for or against the diagnosis of cancer. Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Tumor markers can be found in the blood, the urine, the tumor tissue, or other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is in the early stages. Some tumor marker levels can also be altered in patients with noncancerous conditions. In individuals who have been diagnosed with certain types of cancer, tumor markers may be useful to monitor the effectiveness of treatment and to detect possible recurrence of the cancer. For some cancers, the level of a ...
In cases with findings on examination or imaging tests that suggest cancer, measuring blood levels of tumor markers may provide additional evidence for or against the diagnosis of cancer. Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Tumor markers can be found in the blood, the urine, the tumor tissue, or other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is in the early stages. Some tumor marker levels can also be altered in patients with noncancerous conditions. In individuals who have been diagnosed with certain types of cancer, tumor markers may be useful to monitor the effectiveness of treatment and to detect possible recurrence of the cancer. For some cancers, the level of a ...
In cases with findings on examination or imaging tests that suggest cancer, measuring blood levels of tumor markers may provide additional evidence for or against the diagnosis of cancer. Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Tumor markers can be found in the blood, the urine, the tumor tissue, or other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is in the early stages. Some tumor marker levels can also be altered in patients with noncancerous conditions. In individuals who have been diagnosed with certain types of cancer, tumor markers may be useful to monitor the effectiveness of treatment and to detect possible recurrence of the cancer. For some cancers, the level of a ...
In cases with findings on examination or imaging tests that suggest cancer, measuring blood levels of tumor markers may provide additional evidence for or against the diagnosis of cancer. Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Tumor markers can be found in the blood, the urine, the tumor tissue, or other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is in the early stages. Some tumor marker levels can also be altered in patients with noncancerous conditions. In individuals who have been diagnosed with certain types of cancer, tumor markers may be useful to monitor the effectiveness of treatment and to detect possible recurrence of the cancer. For some cancers, the level of a ...
In cases with findings on examination or imaging tests that suggest cancer, measuring blood levels of tumor markers may provide additional evidence for or against the diagnosis of cancer. Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Tumor markers can be found in the blood, the urine, the tumor tissue, or other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is in the early stages. Some tumor marker levels can also be altered in patients with noncancerous conditions. In individuals who have been diagnosed with certain types of cancer, tumor markers may be useful to monitor the effectiveness of treatment and to detect possible recurrence of the cancer. For some cancers, the level of a ...
Carbohydrate Antigen (CA) 19-9 blood test is ordered to monitor pancreatic, liver, gastrointestinal, and colorectal malignancies.
Carbohydrate Antigen (CA) 19-9 (LabCorp). Get know how much does lab test cost. Direct access testing with or without insurance.
Participants achieved an objective response if they had a best overall response of CR or PR.Target lesions- CR:Disappearance of all lesions;any pathological lymph nodes must have reduction in short axis to ,10 mm.PR: At least a 30% decrease in the sum of diameters of lesions vs the baseline sum.PD: At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study(the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s).Non target lesions - CR: Disappearance of all lesions and normalization of tumour marker levels;all lymph nodes must be non-pathological in size. Non-CR/Non-PD:Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels.PD:Unequivocal progression of existing lesions or the appearance of new lesion(s).If a participant was not known to have died or have radiographically documented PD as of the data inclusion cutoff date,DOR was censored at the date of the last adequate tumor assessment ...
National Honor Society Character Essay Essays and Research Papers. Vasquez National Honors Society Essay To me, National Honors . Society s four pillars are essential elements to being a member of this society . Scholarship and leadership are the two pillars that I feel complement each other because one should be a leader in of fear the community and school without forgetting to be a good student and Essay on Video and Violence: Cause,, scholar. Service and the color of fear, character go well together because in order to provide services to The Relationship Endoscopy Results Tumor Marker Levels Dyspepsia students or members of the community, it is necessary to of fear summary have a good character in order. 927 Words , 2 Pages. Honor Society and Between Results Tumor Marker Levels, National Junior Honor. National Junior Honor Society Essay National Junior Honor . Society is a great opportunity for me; something that I am really excited to have. The Color Of Fear! I would love to be involved in ...
A CT scan performed after three weeks of treatment showed no visible change in the pancreatic mass. A repeat CA 19-9 level at this time showed significant reduction with a value of 204. Subsequent tumor marker levels measured on 12/9/03 and 4/19/04 reported values of 89 and 29 respectively. Coincident with these laboratory findings, patient reported relief from her abdominal pain, increased energy levels, and improved appetite. There were no chemotherapy associated side -effects resulting from this treatment.. A CT Scan from 3/12/03 concluded, no findings to suggest definitive progression of disease or metastatic involvement. A subsequent PET scan done on 3/26/03 reported, no convincing evidence of residual or recurrent tumor.. The patients gallbladder had shown problematic findings since the onset of her illness, and a cholecystectomy was performed on 4/10/03. Subsequently, a CT Scan on 8/20/03 showed a small mass on the head of the pancreas measuring 2×2 cm. A second round of IPT was ...
2015 CA Tumor Marker Testing Technologies and Emerging Markets Published by VPGMarketResearch.com at researchbeam.com [Report Price $3500] 278 Pages
Abfall nachweisen läßt. oder Spende per Überweisung : Krebs-Kompass Forum > Krebsarten > Hautkrebs: Tumormarker MIA beim Melanom. Preklad.
This study compared the sensitivity and specificity of CA 50 and CA 19-9 as serum tumour markers for pancreatic cancer. One hundred and seventy one subjects were evaluated: 50 healthy controls, 50 patients with pancreatic carcinoma and 71 patients with chronic pancreatitis. Eighty per cent of the pancreatic cancer patients had raised CA 19-9 serum levels and 82% had raised CA 50 serum levels. In the group of patients ith chronic pancreatitis, false positive tests occurred in 8.4% for CA 19-9 and 11.3% for CA 50. For both markers the serum level showed a severe elevation in the advanced stage of cancer disease. Despite the good sensitivity and specificity of CA 50 as a serum tumour marker for pancreatic carcinoma, no major advantage was found compared to CA 19-9. Moreover, if the CA 50 cut-off, level is raised to 85 U/ml to exclude overlap with chronic pancreatitis, sensitivity falls sharply to 46% compared with 72% for CA 19-9 when a 100 U/ml cut-off level is used.. ...
Review A Dictionary to Tumor Markers and The Methods of Estimation Rahul R Nair, Jerin K Johnson protein(AFP), Carcinoembryonic antigen(CEA), Pancreatic oncofetal antigen) Abstract Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in the urine, in the tumor tissue, or in other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is early stage. Some tumor marker levels can also be altered in patients with noncancerous conditions. To date, researchers have identified more than a dozen substances that seem to be expressed abnormally when some types of cancer are present. Some of these substances are also found in other conditions and diseases. Scientists ...
CA 19-9 (Carbohydrate Antigen 19-9) conversion to U/mL, kU/L . Online conversion calculator for many types of measurement units in laboratory and medicine CA 19-9 (Carbohydrate Antigen 19-9), CA 19-9, Cancer Antigen 19-9, Gastrointestinal Cancer Antigen.
Tumor markers are substances that can often be detected in higher than normal amounts in the blood, urine, or body tissues of some patients with certain types of cancer. These substances can be proteins, enzymes, biochemicals, or antigens. Tumor markers may either be produced by the cancer itself or by the body in response to the cancer. In general, tumor marker levels are lower in early stage disease (but still higher than normal) and higher with advanced disease. Furthermore, their levels decrease in response to treatment and increase when the cancer progresses.. Tumor markers are often used to:. ...
Adding cisplatin to the current standard of care doublet in advanced pancreatic cancer significantly extends overall survival beyond 1 year.
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
[96 Pages Report] Check for Discount on Global and China Tumor Marker Testing Market Size, Status and Forecast 2020-2026 report by QYResearch Group. Global Tumor Marker Testing Scope and Market Size Tumor Marker...
Researchers at Sydneys Garvan Institute of Medical Research have discovered two biomarkers which indicate the likelihood of patient survival after surgery.
The Hospital Tumor Marker market report breaks down the keyword market into various segments - product type, end users, region and market players.
By navigating this website you provide your agreement to the use of cookies, which we use to improve your navigation experience and for statistical analysis. Read our Cookie Policy to learn more ...
Background: Cancer antigen 15-3 and carcinoembryonic antigen are used in clinical and laboratory diagnosis of metastatic breast cancer. Previous studies have noted conflicting results about the association between carcinoembryonic antigen and cancer antigen 15-3 in metastatic breast cancer. The present study examined serum tumor marker levels of carcinoembryonic antigen and cancer antigen 15-3 among patients with different subtypes of metastatic breast cancer.Methods: In this cross-sectional study, we assessed metastatic breast cancer patients diagnosed between 2005 and 2012 who referred to academic Hospitals affiliated with Mashhad University of Medical Sciences. The patients were selected by systematic randomization sampling. Demographic, clinical, pathological, and therapeutic data were collected from patients hospital records. Statistical analyses were performed by Statistical Package for the Social Sciences version 16.0 software.Results: A total of 298 eligible patients enrolled in the study.
Stage I is divided into stage IA, stage IB, and stage IS, and is determined after a radical inguinal orchiectomy (surgery to remove the testicle) is done. In stage IA, cancer is in the testicle and epididymis and may have spread to the inner layer of the membrane surrounding the testicle; all tumor marker levels are normal. In stage IB, cancer is in the testicle and the epididymis and has spread to the blood or lymph vessels in the testicle; or has spread to the outer layer of the membrane surrounding the testicle; or is in the spermatic cord or the scrotum and may be in the blood or lymph vessels of the testicle; all tumor marker levels are normal. In stage IS, cancer is found anywhere within the testicle, spermatic cord, or the scrotum, and either all tumor marker levels are slightly above normal or one or more tumor marker levels are moderately above normal or high ...
TY - JOUR. T1 - Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy. T2 - A pooled analysis of 6 prospective trials. AU - Bauer, Todd M.. AU - El-Rayes, Bassel F.. AU - Li, Xiaobai. AU - Hammad, Nazik. AU - Philip, Philip A.. AU - Shields, Anthony F.. AU - Zalupski, Mark M.. AU - Bekaii-Saab, Tanios. PY - 2013/1/15. Y1 - 2013/1/15. N2 - Background: Carbohydrate antigen 19-9 (CA19-9) is a widely used biomarker in pancreatic cancer. There is no consensus on the interpretation of the change in CA19-9 serum levels and its role in the clinical management of patients with pancreatic cancer. Methods: Individual patient data from 6 prospective trials evaluating gemcitabine-containing regimens from 3 different institutions were pooled. CA19-9 values were obtained at baseline and after successive cycles of treatment. The objective of this study was to correlate a decline in CA19-9 with outcomes while ...
CCL Dec - Onivyde Combination Boosts OS in Post-Gemcitabine Pancreatic Cancer Patients - Onivyde Combination Boosts OS in Post-Gemcitabine Pancreatic Cancer Patients   A phase III study of Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, demonstrated improvements in median overall survival in post-gemcitabine metastatic pancreatic cancer patients. The study, NAPOLI-1, was the basis of approval by the FDA in this indication, and the results were recently published in The Lancet.
Only a few markers have been instrumental in the diagnosis of cancer. In contrast, tumor markers play a critical role in the monitoring of patients. The patients clinical status and response to treatment can be evaluated rapidly using the tumor marker half-life (t(1/2)) and the tumor marker doubling time (DT). This report reviews the interest of determining these kinetic parameters for prostate-specific antigen, human chorionic gonadotropin, alpha-fetoprotein, carcinoembryonic antigen, cancer antigen (CA) 125, and CA 15-3. A rise in tumor markers (DT) is a yardstick with which benign diseases can be distinguished from metastatic disease, and the DT can be used to assess the efficacy of treatments. A decline in the tumor marker concentration (t(1/2)) is a predictor of possible residual disease if the timing of blood sampling is soon after therapy. The discrepancies in results obtained by different groups may be attributable to the multiplicity of immunoassays, the intrinsic characteristics of each
Tumor markers are substances found in the blood, urine or body tissues that can be elevated in cancer. There are many different tumor markers. They are used in oncology to help determine the presence of cancer. An elevated level of a tumor marker can indicate cancer, however there can often also be other causes of the elevation.. Tumor markers can be produced directly by the tumor or by non-tumor cells as a response to the presence of a tumor. Tumor markers can be used in screening programs, such as screening for elevated levels of prostate specific antigen (PSA) to indicate possible prostate cancer. Tumor markers are also used to monitor patients for cancer return. Tumor markers can be classified in two groups: Cancer-specific markers and tissue-specific markers.. Adenoid Cystic Carcinoma. Ki- ...
Carbohydrate antigen (CA19-9) is a protein that is found in very small amounts on the surface of certain cancer cells. It may be found in the blood when it is shed by tumour cells. It is also found in trace amounts in the pancreas, liver, gall bladder and lungs of healthy adults.
Pancreatic cancer happens when abnormal cells in the pancreas grow out of control and form a tumor, which is an abnormal mass of tissue.. Advanced pancreatic cancer means the cancer has spread from the pancreas to other parts of the body.. Advanced metastatic pancreatic cancer means that the cancer has spread through the bloodstream, or the lymphatic system, to other organs in the body.. The liver is the most common place for it to spread to.. It could also spread to:. ...
ORLANDO -- The addition of Avastin (bevacizumab) to Gemzar (gemcitabine) did not improve survival of advanced pancreatic cancer in a randomized trial, researchers here reported.
3., determination of bone-turnover markers using immunoassays and molecular biological methods.. Serum tumor marker determinations. The majority of these tests (11 analytes: PSA, free PSA, CEA, AFP, HCG-β, CA125, CA15-3, CA19-9, CA72-4, Cyfra 21-1, NSE) are measured by a Roche MODULAR E170 analyzer. Two markers (Thyreoglobulin and TPA) are performed by the Immunochemistry Division, while Calcitonin is measured by the Endocrinology Division of the Department. The interest in the serum tumor marker determination is increasing constantly since the foundation of the division. The number of tests was 8,500 in 2000 while 61,000 in 2009. Due to the increasing number of tests we changed the frequency of measurement and provide results each day of a week.. Molecular Oncology. The diagnostic tests using molecular biological methods can be grouped into two major profiles. The first group of assays - together with the flow cytometric determinations - serves the diagnostics and follow-up of the ...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
Alpha-fetoprotein (AFP) is used as a tumor marker to help detect and diagnose cancers of the liver, testicles, and ovaries. An AFP test may be ordered, along with imaging studies, to try to detect liver cancer when it is in its earliest and most treatable stages.
Tumor markers SlideShare - Deren erhöhte Konzentration kann auf einen Tumor oder das Rezidiv eines Tumors hindeuten. Aufgrund oft geringer Spezifität sind die meisten Tumormarker weniger zum Screening als zur Verlaufskontrolle von Krebs geeignet. Tumormarker gehören zu den Biomarkern Beispiele einzelner Vertreter. Einige Tumormarker sind wesentlich besser unter ihrer Abkürzung als unter dem vollen Namen bekannt.
Tumor Markers: Unlocking the Mistery of the Genetic Basis of Cancer--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence Published by VPGMarketResearch.com at researchbeam.com [Report Price $15900] 1200 Pages
CA50, 0.5 mg. Cancer antigen 50 (CA50), a carcinoma associated carbohydrate antigen, has been found to be elevated in the blood of patients with colorectal cancer and other malignancies.
Many people have been asking me what happened? I thought it might be wise to just tell a few more details for those of you who would like to know. I promise to keep the majority of my post much shorter. Over the last several months Ive been having one of my tumor markers consistently…
Many people have been asking me what happened? I thought it might be wise to just tell a few more details for those of you who would like to know. I promise to keep the majority of my post much shorter. Over the last several months Ive been having one of my tumor markers consistently…
MANHATTAN BEACH, Calif., Nov. 9, 2012 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce Abraxane® extends survival for patients with advanced pancreatic cancer. According to Celgene Corporation, Abraxane in combination with gemcitabine when given to advanced pancreatic cancer patients who had not received previous treatment demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. (Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO). The phase III study included 861 metastatic pancreatic cancer patients from around the world. Full results from the clinical trial will be presented at the American Society of Clinical Oncologys 2013 Gastrointestinal Cancers Symposium being held in January. Historically, few effective treatment options for pancreatic cancer have existed. We are thrilled to have a new treatment option for patients with advanced pancreatic cancer. We look forward to learning more ...
TY - JOUR. T1 - Palliative care in advanced pancreatic cancer. AU - Muircroft, Wendy. AU - Currow, David. PY - 2016/3. Y1 - 2016/3. N2 - The management of patients with advanced pancreatic cancer often requires a multi-disciplinary approach with individualised therapy. Addressing the underlying causes of several of the troublesome symptoms that are relatively unique to the pathophysiology of pancreatic cancer is crucial in order to optimise the function and comfort of people diagnosed with this poor prognosis cancer. Early recognition and response is likely to improve outcomes later in the course of the disease, but more work needs to be done to compare expectant and reactive approaches to the most troublesome symptoms in advanced pancreatic cancer. Given such a poor outlook, referral to a palliative care service that has an active, team-based approach that includes dietetics, gastroenterology, interventional pain expertise and liaison psychiatry is likely to deliver the best possible outcomes. ...
Measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers is simple, objective, reproducible and cost effective. The most widely used markers are a MUC1 mucin (e.g. measured as CA15.3) and CEA. A combination of markers is more sensitive than using a single marker. When CA15.3, CEA and ESR are used as a panel of serum markers in monitoring therapeutic response, over 90% of patients are biochemically assessable. A biochemical index score comprising these three markers has been devised retrospectively, validated prospectively, in a single centre and in a multicentre study. Biochemical assessment by serum markers correlates with clinical/radiological (UICC) assessment and often pre-dates remission and progression shown by UICC criteria. It is also the only validated method in monitoring metastatic breast cancer with disease unassessable by UICC criteria (e.g. sclerotic bone metastases, irradiated lesions). Future studies should aim at incorporating new ...
Purpose To assess the immunomodulatory and clinical effects of lenalidomide with standard treatment of gemcitabine in patients with advanced pancreatic cancer. Patients and Methods Patients with advanced pancreatic cancer were treated in first line with lenalidomide orally for 21 days of a 28 days cycle and the standard regimen for gemcitabine. In Part I, which we previously have reported, the dose of lenalidomide was defined (n = 12). In Part II, every other consecutive patient was treated with either lenalidomide (Group A, n = 11) or gemcitabine (Group B, n = 10) during cycle 1. From cycle 2 on, all Part II patients received the combination. Results A significant decrease in the proliferative response of peripheral blood mononuclear cells and the frequency of DCs were noted in patients at baseline compared to healthy control donors while the frequencies of CD4+ and CD8+ T cells, NK-cells and MDSCs were significantly higher in patients compared to controls. In Group A, a significant increase in ...
20 ng/ml) serum Tg levels and negative Anti TgAb. In 75 patients (8.4% of patients or 63% of the Tg+ve subgroup), elevated Tg levels correlated well with positive 131I imaging. In 13 patients with positive correlation Tg/131I WBS, WBS revealed pulmonary (12 pts) or bone (1 pt) metastases, with no uptake in the cervical region. Moreover, 45 patients (5% of all patients or 37.5% of the Tg+ve group) presented discordant elevated Tg levels and negative Anti TgAb but negative WBS imaging. Using the same immune-radiometric method, with optimal sensitivity for Tg and without reported Hook effect for Anti TgAb, we found in 9% of patients the presence of strong positive Anti Tg, interfering with the Tg assay and underestimating serum Tg levels. From 890 patients sera, in 79 % Anti TgAb were < 35 mUI/ml (negative value), 8 % were equivocal (35-65%) and 12 % were strongly positive ( >65 mUI/ml). Conclusions: Detectable or elevated Tg concentrations most often correlate with 131I uptake, allowing ...
Practice-changing results show that adjuvant therapy with modified FOLFIRINOX significantly boosted both disease-free and overall survival in resectable pancreatic cancer.
Tumor markers are substances that are produced by the body in response to cancer or other certain benign (non-cancerous) conditions. These substances can be found in samples of blood, tumor tissue, urine, stool and other bodily fluids of some cancer patients.. Tumor markers are useful in helping to detect, diagnose and manage some types of cancers. The level of tumor marker present can sometimes reflect the stage (extent) of the disease or the patients prognosis (the likely outcome or the course of disease) for some types of cancers. Tumor markers can also be periodically measured during any cancer therapy treatment, where a decrease in level or a return to normal level for the markers can indicate that the treatment is working and the cancer is responding positively. These markers are also often measured after a treatment has ended in order to check for recurrence (i.e. the return of cancer).. Many different tumor markers have been characterized extensively and used for many clinical ...
Fasting Required: No Specimen: Blood Results: 1-2 Business Days Description: Cancer antigen (CA) 27.29 is used to monitor metastatic carcinoma of the...
The tumor marker CA242 is defined by the monoclonal antibody C242. The chemical structure of the antigenic determinant is not exactly known, but the determinant have been shown to be a sialylated carbohydrate structure. In serum, CA242 is found on the same mucin-complex as CA50 and sialylated Lewisa (CA19-9). Thus, CA242 is related, but not identical to the epitope of CA19-9 (1, 2). Serum levels of CA242 are low in healthy subjects and subjects with benign diseases, while elevated levels are commonly found in serum from patients with gastro-intestinal cancer (3). The CA242 marker may be used as an aid in the diagnosis and management of patients with known or suspected gastro-intestinal carcinomas (4-9). The CanAg CA242 EIA should not be used as a substitute for any established clinical examination of malignancy, but may be used as a complement to existing clinical and laboratory methods. ...
In 2008, an estimated 217 000 new cases of pancreatic cancer were diagnosed worldwide, and in the UK 8000 new cases of pancreatic cancer are reported every year.4 5 6 Worldwide, pancreatic cancer is 13th in incidence but 8th in terms of cancer death.4 In the UK, pancreatic cancer is the 5th most common cause of cancer death in both sexes, despite being only the 11th most common cancer overall.7 This is largely due to red flag symptoms usually appearing only once the disease has progressed to involve other structures. Consequently, only 10-20% of patients will have resectable pancreatic cancer at presentation.7 ...
This book is a comprehensive introduction to the expression of tumor markers in association with various neoplasms, the methods used in their detection and their clinical relevance to the diagnosis and treatment of cancer. It will be an invaluable guide for clinicians, pathologists and research workers requiring an in-depth introduction to this subject and, with sections devoted to the exploitation of new techniques in immunohistochemistry, flow cytomtry, cancer genetics and molecular biology for the identification of tumor markers, can also be used as a laboratory reference.
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
The primary end point is to evaluate the time to progression after gemcitabine alone versus Gemcitabine-based combination induction chemotherapy followe
Author: Almeida, Andreia et al.; Genre: Journal Article; Published in Print: 2016; Keywords: Serum tumour markers; Title: The promise of protein glycosylation for personalised medicine
This new report from VPGMarketResearch.com contains 525 pages, 38 tables, and presents a comprehensive analysis of the Italian hospital tumor marker testing market, ...
... antigen and cannot produce CA19-9. It has a sensitivity of 80% and specificity of 73% in detecting pancreatic adenocarcinoma, ... CA19-9 (carbohydrate antigen 19.9) is a tumor marker that is frequently elevated in pancreatic cancer. However, it lacks ... CA: A Cancer Journal for Clinicians. 63 (5): 318-48. doi:10.3322/caac.21190. PMC 3769458. PMID 23856911. Vincent A, Herman J, ... See p. 4 for incidence estimates, and p. 19 for survival percentages. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, ...
Liver markers that can be increased with intrahepatic CCA are carcinoembryonic antigen (CEA), CA19-9, and CA-125. These are ... carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). These tumor markers are found in primary liver cancers, as well ... Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (Mar-Apr 2011). "Global cancer statistics". CA. 61 (2): 69-90. doi: ... Cholangiocarcinoma can be detected with these commonly used tumor markers: carbohydrate antigen 19-9 (CA 19-9), ...
During her postdoctoral studies, Engle focused her efforts on probing a specific carbohydrate antigen, CA19-9, released by ... "CA 19-9". Pancreatic Cancer Action Network. Retrieved 2020-03-24. Engle, Dannielle D.; Tiriac, Hervé; Rivera, Keith D.; Pommier ... After her undergraduate degree, Engle pursued graduate school at the University of California San Diego. During this time, ... DOI: 10.1101/gad.2024411 "Research Grantee Studies Link Between Pancreatic Cancer and CA19-9 - Pancreatic Cancer Action ...
This is because of a deficiency of a fucosyltransferase enzyme that is needed to produce Lewis antigen A. CA19-9 was discovered ... Goonetilleke KS, Siriwardena AK (April 2007). "Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in ... In patients who lack the Lewis antigen A (a blood type antigen on red blood cells), which is about 10% of the Caucasian ... Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) CA19-9 at Lab Tests Online CA19-9: analyte ...
The utility of CEA (Carcinoembryonic antigen) and CA19-9 as colorectal carcinoma (CRC) markers is limited and development of ... Recommended name:Galectin-4, Short name: Gal-4 Alternative name(s): Antigen NY-CO-27 L-36 lactose-binding protein, Short name: ... Ideo H, Seko A, Yamashita K (2005). "Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on ... 282 (29): 21081-9. doi:10.1074/jbc.M703770200. PMID 17545668. (Articles with short description, Short description matches ...
... carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). These tumour markers are found in primary liver cancers, as well ... CA 19-9), ...
... carbohydrate antigens CA 19-9 and CA 724 in the diagnosis of gastrointestinal cancer". Anticancer Res. 23 (6D): 5089-5095. PMID ... The combination of Tumor M2-PK with the appropriate classical tumor marker, such as CEA for bowel cancer, CA 19-9 for ... Schneider J, Schulze G (2003). "Comparison of Tumor M2-pyruvate kinase (Tumor M2-PK), carcinoembryonic antigen (CEA), ... CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions". Anticancer Res. 19 (1B): 849-52. PMID ...
Serum levels of carcinoembryonic antigen (CEA) and CA19-9 are often elevated, but are not sensitive or specific enough to be ... Studies of the performance of serum markers for cholangiocarcinoma (such as carcinoembryonic antigen and CA19-9) in patients ... Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD (September 2005). "The value of serum CA 19-9 in predicting ... Rustagi T, Dasanu CA (June 2012). "Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and ...
... carcinoembryonic antigen (CEA) and CA 125 are abnormally high in the bloodstreams of patients with intrahepatic ... The serum CA 19-9 in particular may be very high. The ultrasonography (and the use of Doppler modes) permit definitive ... Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR (2004). "Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison ... Levels of the tumor markers carbohydrate antigen 19-9 (CA 19-9), ...
... antigens, cd15 MeSH D23.050.285.050.115 - ca-15-3 antigen MeSH D23.050.285.050.119 - ca-19-9 antigen MeSH D23.050.285.050.225 ... antigens, cd15 MeSH D23.050.550.325.115 - ca-15-3 antigen MeSH D23.050.550.325.119 - ca-19-9 antigen MeSH D23.050.550.325.225 ... antigens, cd15 MeSH D23.101.840.075.115 - ca-15-3 antigen MeSH D23.101.840.075.119 - ca-19-9 antigen MeSH D23.101.840.075.225 ... antigens, cd15 MeSH D23.101.100.900.131 - antigens, cd31 MeSH D23.101.100.920 - antigens, ly MeSH D23.101.100.930 - antigens, ...
"The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA". Annals of Clinical Biochemistry. 35 ( ... Carcinoembryonic+Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) CEA at Lab Tests Online CEA: ... Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally ... Asad-Ur-Rahman F, Saif MW (June 2016). "Elevated Level of Serum Carcinoembryonic Antigen (CEA) and Search for a Malignancy: A ...
... levels of CA 19-9 are typically undetectable or below 1.0 U/ml. GRUBB R (1948). "Correlation between Lewis blood group and ... Lewis antigens are red blood cell antigens which are not produced by the cell itself. Instead, Lewis antigens are components of ... the A antigen results and the person is type A. When the B gene product acts on the H antigen to add a galactose, the B antigen ... If no further modifications are made to the H antigen, the person is type O. When the A gene product acts on the H antigen and ...
Stewart EH, Davis B, Clemans-Taylor BL, Littenberg B, Estrada CA, Centor RM (2014-11-04). "Rapid antigen group A streptococcus ... for influenza virus antigens) Malaria antigen detection tests (for Plasmodium antigens) Rapid antigen tests for COVID-19 are ... A rapid antigen test (RAT), sometimes called a rapid antigen detection test (RADT), antigen rapid test (ART), or loosely just a ... RATs are based on the principle of antigen-antibody interaction. Antibodies directed against the target antigen (generally a ...
CA19-9 (Sialyl-Lewis A) Pang, Poh-Choo; Chiu, Philip C. N.; et al. (18 August 2011). "Human Sperm Binding Is Mediated by the ... Sialyl Lewis X is also one of the most important blood group antigens and is displayed on the terminus of glycolipids that are ... Sialyl Lewis x is also an inflammation-associated antigen on liver cells. It becomes over expressed on diseased liver cells and ... Sialyl LewisX (sLeX), also known as cluster of differentiation 15s (CD15s) or stage-specific embryonic antigen 1 (SSEA-1), is a ...
Arce-Gomez B, Jones EA, Barnstable CJ, Solomon E, Bodmer WF (Feb 1978). "The genetic control of HLA-A and B antigens in somatic ... Barnes CA, McNamara S, O'Riordan J, McCann SR, Darke C (1997). "Distribution of HLA-A, B and DR genes and haplotypes in the ... HLA-A*02 (A*02) is a human leukocyte antigen serotype within the HLA-A serotype group. The serotype is determined by the ... The HLA-A*02 antigen has been associated with spontaneous abortion in infertile couples. In essence, there are indicators, ...
Stanford DR, Perry CA, Holicky EL, Rohleder AM, Wieben ED (November 1988). "The small nuclear ribonucleoprotein E protein gene ... Stanford DR, Rohleder A, Neiswanger K, Wieben ED (July 1987). "DNA sequence of a human Sm autoimmune antigen. The multigene ... Stanford DR, Kehl M, Perry CA, Holicky EL, Harvey SE, Rohleder AM, Rehder K, Luhrmann R, Wieben ED (November 1988). "The ... 237 (1): 63-9. doi:10.1006/excr.1997.3750. PMID 9417867. Kambach C, Walke S, Young R, Avis JM, de la Fortelle E, Raker VA, ...
2004). "Association between expression levels of CA 19-9 and N-acetylglucosamine-beta;1,3-galactosyltransferase 5 gene in human ... 2003). "Lewis type 1 antigen synthase (beta3Gal-T5) is transcriptionally regulated by homeoproteins". J. Biol. Chem. 278 (38): ...
Janeway CA, Jr (1 November 2013). "Pillars article: approaching the asymptote? Evolution and revolution in immunology. Cold ... T-independent antigen - Antigens that stimulate B cells directly. Immunodominant antigens - Antigens that dominate (over all ... A native antigen is an antigen that is not yet processed by an APC to smaller parts. T cells cannot bind native antigens, but ... Antigens can be classified according to their source. Exogenous antigens are antigens that have entered the body from the ...
2. Thousand Oaks, California, USA: Magnum Publishing. pp. 268-269. ISBN 0-9716146-0-1. Retrieved 19 April 2011. Kennedy, L. J ... Day, M.J (1999). "Antigen specificity in canine autoimmune haemolytic anaemia". Veterinary Immunology and Immunopathology. 69 ( ... Tissue Antigens. 66 (6): 656-65. doi:10.1111/j.1399-0039.2005.00508.x. PMID 16305682. Cottelll, Beverley D.; Barnett, K. C. ( ... Tissue Antigens. 68 (1): 82-6. doi:10.1111/j.1399-0039.2006.00614.x. PMID 16774545. S2CID 358248. "The Akita - Diseases" ( ...
Mouse CD Antigen Chart Human CD Antigen Chart Human CD19 genome location and CD19 gene details page in the UCSC Genome Browser ... Khine AA, Firtel M, Lingwood CA (August 1998). "CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional ... B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12 and CVID3 is a transmembrane protein that in humans is encoded ... Recognition of an antigen by the complement system enables the CD19/CD21 complex and associated intracellular signaling ...
Vilchez RA, Kozinetz CA, Arrington AS, Madden CR, Butel JS (June 2003). "Simian virus 40 in human cancers". The American ... September 2009). "Detection of human herpesvirus-6 variants in pediatric brain tumors: association of viral antigen in low ... "University of California, Los Angeles Neuro-Oncology : How Our Patients Perform : Glioblastoma Multiforme [GBM]". Archived from ... CA: A Cancer Journal for Clinicians. 60 (3): 166-93. doi:10.3322/caac.20069. PMC 2888474. PMID 20445000. McKenney, Anna Sophia ...
Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y (2004). "CATs and HATs: the SLC7 family of amino acid transporters ... 4F2 cell-surface antigen heavy chain is a protein that in humans is encoded by the SLC3A2 (solute carrier family 3 member 2) ... Teixeira S, Di Grandi S, Kühn LC (August 1987). "Primary structure of the human 4F2 antigen heavy chain predicts a ... Haynes BF, Hemler ME, Mann DL, Eisenbarth GS, Shelhamer J, Mostowski HS, Thomas CA, Strominger JL, Fauci AS (1981). " ...
Erlanson M, Casiano CA, Tan EM, et al. (1999). "Immunohistochemical analysis of the proliferation associated nuclear antigen ... Rattner JB, Rao A, Fritzler MJ, Valencia DW, Yen TJ (Mar 1994). "CENP-F is a .ca 400 kDa kinetochore protein that exhibits a ... 15 (9): 5017-29. doi:10.1128/MCB.15.9.5017. PMC 230749. PMID 7651420. Li S, Ku CY, Farmer AA, et al. (1998). "Identification of ... 1 (2): 141-9. PMID 12467231. Konstantinidou AE, Korkolopoulou P, Kavantzas N, et al. (2003). "Mitosin, a novel marker of cell ...
San Diego, CA. Abstract #2326. Messmann R, Amato R, Hernandez-McClain J, Conley B, Rogers H, Lu J, Low P, Bever S, Morgenstern ... The FR is also a recognized tumor antigen/biomarker. Because of this, diagnostic and therapeutic methods which exploit the FR's ... Luhrs CA, Slomiany BL (December 1989). "A human membrane-associated folate binding protein is anchored by a glycosyl- ... November 1991). "Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein". Cancer ...
Antibody-induced Loss of Friend Virus Leukemia Cell Surface Antigens Occurs During Progression of Erythroleukemia in F1 Mice. ( ... Also published in the San Jose (CA) newspapers. The Ministry of Science. Inquiry, December, 1983, pp. 20-23. Farming Washington ... Antibody-Induced Modulation of Friend Virus Cell Surface Antigens Decreases Virus Production by Persistent Erythroleukemia ... "Antibody-Induced Modulation of Friend Virus Cell Surface Antigens Decreases Virus Production by Persistent Erythroleukemia ...
Antigen stimulation of immune cells triggers Ca2+ entry through tetrameric Ca2+ release-activated Ca2+ (CRAC) channels, ... Cahalan MD (June 2009). "STIMulating store-operated Ca(2+) entry". Nature Cell Biology. 11 (6): 669-77. doi:10.1038/ncb0609-669 ... "Differential STIM1 expression in T and B cell subsets suggests a role in determining antigen receptor signal amplitude". ... 19 (20): 1724-9. doi:10.1016/j.cub.2009.08.022. PMC 3552312. PMID 19765994. Cheng KT, Liu X, Ong HL, Ambudkar IS (May 2008). " ...
Baldo L, Desjardins CA, Russell JA, Stahlhut JK, Werren JH (2010-02-17). "Accelerated microevolution in an outer membrane ... "Onchocerciasis modulates the immune response to mycobacterial antigens". Clinical and Experimental Immunology. 117 (3): 517-523 ... Retrieved 2021-09-19. James, William D.; Berger, Timothy G.; Elston, Dirk M; Odom, Richard B. (2006). Andrews' Diseases of the ... 129 (3): 260-9. doi:10.1111/j.1365-2133.1993.tb11844.x. PMID 8286222. S2CID 42108950. Abiose, Adenike (March 1993). "A clinical ...
Prostate-specific antigen (PSA) is secreted by the epithelial cells of the prostate gland and can be detected in a sample of ... San Diego, CA: Hologic, Inc.; 2015. Kim, Hojun; Park, Sungwook; Jeong, In Gab; Song, Sang Hoon; Jeong, Youngdo; Kim, Choung-Soo ... Prostate cancer antigen 3 (PCA3) is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate ... A PSA test cannot 'prove' the existence of prostate cancer by itself; varying levels of the antigen can be due to other causes ...
CA 125 Breast: CEA, CA 15-3, Cyfra 21-1 Ovary: CEA, CA 19-9, CA 125, AFP, BHCG Uterine: CEA, CA 19-9, CA 125, Cyfra 21-1, SCC ... Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M (January 2008). "Value of cancer antigen 125 for ... "Definition of CA 27-29. From MedicineNet. Last Editorial Review: 6/14/2012". gpnotebook.co.uk > ca-19-9 Retrieved November 2011 ... CA 72-4 Liver: CEA, AFP Oesophagus: CEA, Cyfra 21-1 Thyroid: CEA, NSE Lung: CEA, CA 19-9, CA 125, NSE, Cyfra 21-1 (Sensitivity ...
Dendritic cells are antigen presenting cells (APCs) in the mammalian immune system. In cancer treatment they aid cancer antigen ... Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN (January 2013). "Building on ... Unlike CAR-T's cell surface antigens, TCR-T can recognize that larger set of intracellular antigen fragments. However, TCR-T ... Antigens can be added to the antibody and can induce the dendritic cells to mature and provide immunity to the tumor. Dendritic ...
GalNAc and α-D-GalNAc-Ser/Thr (Tn-antigen) WFA Wisteria floribunda vistárie mnohokvětá koncové GalNAc (např. β-D-GalNAc-(1-4)- ... metaloprotein, vyžaduje přítomnost Ca2+ nebo Mg 2+, široká specifita, jeden z nejpoužívanějších lektinů, homotetramer ... metaloprotein, vyžaduje přítomnost Ca2+ nebo Mg 2+, užší specifita než Con A ... β-D-Gal-(1-3)-α-D-GalNAc-Ser/Thr (T-antigen) ... vazebná aktivita závislá na Ca2+) S-typ (galektiny) β-D-Gal ...
Vpu단백질(p16)은 감염된 세포로부터 새로운 바이러스 입자를 방출하는 데 영향을 준다.[57] Gag 유전자는 바이러스 입자를 만드는 중심이 되는 매트릭스 단백질 (MA, Gag p17)과 캡시드 단백질 (CA, Gag ... "HIV-1 Nef impairs MHC class II antigen presentation and surface expression". 》Proc. Natl. Acad. Sci. U.S.A.》 98 (21): 12144-9 ... 2013년 9월 16일에 원본 문서에서 보존된 문서. 2009년 3월 31일에 확인함.. 더 이상 지원되지 않는 변수를 사용함 (도움말) CS1 관리 - et al.의 직접적인 사용 (링크) CS1 관리 - 여러 이름 (링크) ... 사망자의 1/3이 경제성장이 없고 빈곤이 극심한 아프리카의 사하라 이남지방에 집중되어 있다.[4] 또한 HIV는 아프리카에서 9천만명을 감염시켜 최소 천8백만명의 고아를 생기게 한 원인이라고 한다.[5] 항레트로바이러스제 처방은 ...
Exogenous antigensEdit. Antigen presentation stimulates T cells to become either "cytotoxic" CD8+ cells or "helper" CD4+ cells. ... Janeway CA, Travers P, Walport M, Shlomchik MJ (2001). Immunobiology (5th ed.). New York and London: Garland Science. ISBN 0- ... Antigen presentationEdit. Main article: Antigen presentation. Acquired immunity relies on the capacity of immune cells to ... Endogenous antigensEdit. Endogenous antigens are produced by intracellular bacteria and viruses replicating within a host cell ...
Nowson CA, Margerison C. Vitamin D intake and vitamin D status of Australians. The Medical Journal of Australia. August 2002, ... The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced ... 在一项实验中,一些身体健康的年迈女性按照要求补充了钙素补充剂,结果显示血管事件发生的风险提高[8],这导致一些专家开始质疑目前大部分人所认同的通
California government response. *New York government response. *Texas government response. *Eastern States Multi-state Council ... 93 (19). doi:10.1128/JVI.00355-19. PMC 6744225. PMID 31315999.. *↑ Estola T (1970). "Coronaviruses, a New Group of Animal RNA ... 978-0-19-263285-2. .. *↑ Hagan WA, Bruner DW, Gillespie JH, Timoney JF, Scott FW, Barlough JE (1988). Hagan and Bruner's ... 978-3-7643-7339-9. . PMC 7123520. PMID 19184921.. *↑ Naskalska A, Dabrowska A, Szczepanski A, Milewska A, Jasik KP, Pyrc K ( ...
CA, Inc. · Celgene · Cephalon · Cerner · Check Point · Cintas · Cisco · Citrix · Cognizant · Comcast · Քոստքո · Dell · Dentsply ... Microsoft AntiGen. *Microsoft Forefront Client Security. *Microsoft Forefront Security for Exchange. *Microsoft Forefront ... Alliance for Open Media, Լինուքս հիմնադրամ[8][9], Համացանցի կոնսորցիում[10], Վայ-Ֆայ Դաշինք[11], SD Association?[12], OpenID ... 23,0 23,1 «U.S. v. Microsoft: Timeline»։ Wired։ նոյեմբերի 4, 2002։ Արխիվացված է օրիգինալից 2010 թ․ ապրիլի 19-ին։ Վերցված է 2010 ...
n. št.) umorili njegovi generali Pejton, Selevk in Antigen (verjetno s pomočjo Ptolemaja).[12] Ptolemaj se je sporazumel s ... University of California Press. Pages 7-8. *↑ Green (1990), page 9. *↑ Green (1990), page 14. ... Alfred, Randy (June 19, 2008). "June 19, 240 B.C.E: The Earth Is Round, and It's This Big". Wired. Pridobljeno dne 2013-06-22. ... helenist (starogrško Ἑλληνιστής, Hellēnistēs), potrjene že od antičnih časov[6], se je sredi 19. stoletja Johann Gustav Droysen ...
"Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors". Journal of Immunology. 123 (6): 2928-9. ... Schindler R, Dinarello CA (1990). "Interleukin 1". u Habenicht A (ured.). Growth Factors, Differentiation Factors, and ... IL-9. Th2-ćelije, specifične za CD4+ pomoćne ćelije. CD129/IL9R. T-ćelije, B-ćelije. Potencira IgM, IgG, IgE, stimurira ... Interleukin 9[uredi , uredi izvor]. Glavni članak: Interleukin 9. Interleukin 9 (IL-9) je citokin koji podržava IL-2 neovisan i ...
Braig M, Schmitt CA (March 2006). "Oncogene-induced senescence: putting the brakes on tumor development". Cancer Research. 66 ( ... A bypass platform is provided to these polymerases by Proliferating cell nuclear antigen (PCNA). Under normal circumstances, ... Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky SL, Darnell J (2004). Molecular Biology of the Cell ( ... Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, et al. (April 2003). "Exploration of global gene ...
Samuel G, Reeves P (November 2003). "Biosynthesis of O-antigens: genes and pathways involved in nucleotide sugar precursor ... synthesis and O-antigen assembly". Carbohydrate Research. 338 (23): 2503-19. doi:10.1016/j.carres.2003.07.009. PMID 14670712.. ... 11 (11): 1543-9. doi:10.1007/BF00778244. S2CID 1094223.. *^ Percudani R, Peracchi A (September 2003). "A genomic overview of ... Ca2+. *Cu2+. *Fe2+, Fe3+. *Mg2+. *Mn2+ ... 19] Inhibitors[edit]. Several inhibitors of PLP enzymes are ...
Stayboldt C, Rearden A, Lane T (1987). "B antigen acquired by normal A1 red cells exposed to a patient's serum". Transfusion 27 ... Dennis O'Neil, Behavioral Sciences Department, Palomar College, San Marcos, California. 2001-06-06. 2009-12-11 அன்று மூலம் ... Laura Dean, MD (2005). Blood Groups an Red Cell Antigens. National Center for Biotechnology Information, United States ... there are more than 600 known antigens besides A and B that characterize the proteins found on a person's red cells. ...
T. cruzi shed acute-phase antigen (SAPA), which can be detected in blood using ELISA or Western blot,[22] has been used as an ... Echeverria LE, Morillo CA (February 2019). "American Trypanosomiasis (Chagas Disease)". Infectious Disease Clinics of North ... Retrieved 9 March 2020.. *^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap ... Bestetti RB, Martins CA, Cardinalli-Neto A (May 2009). "Justice where justice is due: A posthumous Nobel Prize to Carlos Chagas ...
Instead, one could cleave in a section between the bead and the antigen to elute. Since the pIII is intact it does not matter ... Patent CA 2035384), thereby allowing human antibodies to be created in vitro from synthetic diversity elements. Antibody ... The technique is also used to determine tumour antigens (for use in diagnosis and therapeutic targeting) and in searching for ... novel expression vectors that display cloned antigens on the virion surface". Science. 228 (4705): 1315-7. Bibcode:1985Sci... ...
The ABH-antigen produced is thought to act as a receptor for human norovirus: A non-functional fucosyltransferase FUT2 provides ... MacCannell T, Umscheid CA, Agarwal RK, Lee I, Kuntz G, Stevenson KB (October 2011). "Guideline for the prevention and control ... Tan M, Hegde RS, Jiang X (2004). "The P Domain of Norovirus Capsid Protein Forms Dimer and Binds to Histo-Blood Group Antigen ... Reports have shown a link between the expression of human histo-blood group antigens (HBGAs) and the susceptibility to ...
... and EBV nuclear antigen 2 (EBNA-2) from Epstein-Barr virus, the large T antigen of Polyomavirus, the E7 protein of Human ... Goldstein D, Laszlo J (Sep 1988). "The role of interferon in cancer therapy: a current perspective". CA: A Cancer Journal for ... Interferon gamma (IFN-gamma) also significantly stimulates the MHC II-dependent presentation of antigens. Higher MHC I ... All interferons significantly enhance the presentation of MHC I dependent antigens. ...
More than 11.7 million RT-PCR tests and more than 7.3 million rapid antigen tests have been processed. An anti-COVID-19 ... ca), CS1 German-language sources (de), CS1 Dutch-language sources (nl), CS1 Bulgarian-language sources (bg), CS1 Czech-language ... "COVID-19's epicentre again: Europe faces fresh reckoning". www.aljazeera.com. Retrieved 19 November 2021. "Covid: Half of ... On 9 March, the first case in the Crown dependency was confirmed. On 27 May it was announced that there were no known active ...
Todd WR, Elvejheim CA, Hart EB (1934). "Zinc in the nutrition of the rat". Am J Physiol. 107: 146-156. doi:10.1152/ajplegacy. ... Pra1 (pH regulated antigen 1) is a candida albicans protein that scavenges host zinc. Diagnosis is typically made based on ... Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME (April 2012). "Zinc and human health: an update". Archives of ... "Zinc" Archived 19 September 2017 at the Wayback Machine, pp. 442-501 in Dietary Reference Intakes for Vitamin A, Vitamin K, ...
Lawrence Valley, ca. 5% in southern Manitoba and some northerly parts of Quebec (e.g., Abitibi-Témiscamingue), and ca. 1% in ... In some areas, such as Kansas City, skin testing with the histoplasmin antigen preparation shows that 80-90% of the resident ... Based on numerous small regional studies, histoplasmin skin test reactors form ca. 10-50 % of the population in much of ... Erythematous skin conditions arising from antigen reactions may complicate the disease, as may myalgias, arthralgias, and ...
CA: University of California Executive Yuan, R.O.C. (2014). The Republic of China Yearbook 2014 (PDF). ISBN 9789860423020. ... In 2007, a study by Marie Lin reported that the human leukocyte antigen typing study and mitochondrial DNA analysis ... CA: University of California Press, ISBN 9780936127095. Blust, Robert (1988), Austronesian Root Theory, Amsterdam: John ... Wolf, Arthur; Huang, Chieh-shan (1980), Marriage and Adoption in China, Stanford, CA: Stanford University Press. Wu, David Y.H ...
Patarca R, Freeman GJ, Singh RP, Wei FW, Durfee T, Blattner F, Regnier DC, Kozak CA, Mock BA, Morse III CA, Jerrells TR, Cantor ... Boyse EA, Old LJ, Stockert E. An approach to the mapping of antigens on the cell surface. Proc Natl Acad Sci USA 1968;60:886. ... Glimcher L, Shen F-W, Cantor H. Identification of a cell-surface antigen selectively expressed on the natural killer cell. J. ... Glimcher L, Shen FW, Cantor H. Identification of a cell-surface antigen selectively expressed on the natural killer cell. J Exp ...
Nov-Dec 2012). "Oral complications of cancer and cancer therapy: from cancer treatment to survivorship". CA. 62 (6): 400-422. ... in persons with blood group O and in non-secretors of blood group antigens in saliva. Increased rates of Candida carriage are ... Journal of the California Dental Association. 41 (4): 263-268. PMID 23705242. Yamada T, Alpers DH, et al. (2009). Textbook of ... 19, 21, 92, 93. ISBN 978-1-60327-519-4. Rhodus NL (Mar-Apr 2012). "Treatment of oral candidiasis" (PDF). Northwest Dentistry. ...
OspA antigens, shed by live Borrelia bacteria into urine, are a promising technique being studied. The use of nanotrap ... Walsh CA, Mayer EW, Baxi LV (January 2007). "Lyme disease in pregnancy: case report and review of the literature". Obstetrical ... Hyde FW, Johnson RC, White TJ, Shelburne CE (January 1989). "Detection of antigens in urine of mice and humans infected with ... Jowett N, Gaudin RA, Banks CA, Hadlock TA (June 2017). "Steroid use in Lyme disease-associated facial palsy is associated with ...
For this reason, they are described as H1N1, H1N2 etc., depending on the type of H or N antigens they express with metabolic ... Cbc.ca. Archived from the original on 19 May 2020. Retrieved 10 February 2019. "Un muerto en Coahuila por influenza AH1N1". ... Southern California, March-April 2009". MMWR Morb. Mortal. Wkly. Rep. 58 (15): 400-02. PMID 19390508. Archived from the ... Retrieved 9 June 2021. "Humans May Give Swine Flu To Pigs In New Twist To Pandemic". Sciencedaily.com. 10 July 2009. Archived ...
Klein BK, Feng Y, McWherter CA, Hood WF, Paik K, McKearn JP (1997). "The receptor binding site of human interleukin-3 defined ... IL-3 is produced by T cells only after stimulation with antigens or other specific impulses. However, it was observed that IL-3 ... Le Beau MM, Espinosa R, Neuman WL, Stock W, Roulston D, Larson RA, Keinanen M, Westbrook CA (1993). "Cytogenetic and molecular ... Feng Y, Klein BK, McWherter CA (1996). "Three-dimensional solution structure and backbone dynamics of a variant of human ...
Janeway CA (November 2013). "Approaching the asymptote? Evolution and revolution in immunology". Cold Spring Harbor Symposia on ... PRRs also mediate the initiation of antigen-specific adaptive immune response and release of inflammatory cytokines. The ... Tissue Antigens. 68 (3): 193-209. doi:10.1111/j.1399-0039.2006.00649.x. PMC 7169806. PMID 16948640. Bahar O, Pruitt R, Luu DD, ... Blood DC antigen 2 (BDCA2) ( CLEC4C), and Mincle i.e. macrophage‑inducible C‑type lectin (CLEC4E). The nomenclature (mannose ...
Prostate-specific membrane antigen (PSMA) stimulates cancer development by increasing folate levels, helping the cancer cells ... Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR (June 2005). "The University of California, San ... Filson CP, Marks LS, Litwin MS (8 May 2015). "Expectant management for men with early stage prostate cancer". CA. 65 (4): 265- ... Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M (September 2017). "Laparoscopic and robotic-assisted versus open ...
Foundation Director at California State University in San Francisco, School of Music & Dance; pianist and musician Anne Boyd - ... secretes a specific antibody in response to an encounter with a specific foreign antigen Mitchell Notaras - graduate who funded ... President of the California Institute for Regenerative Medicine John Turtle - former Kellion Professor of Endocrinology ... Professor of Earth and Planetary Science at the University of California, Berkeley Brian O'Brien - physicist and space ...
A 2019 study on the human leukocyte antigen genetics of Mapuche from Cañete found affinities with a variety of North and South ... "El toqui Lautaro (ca.1534-1557)". Memoria Chilena (in Spanish). Biblioteca Nacional de Chile. Retrieved January 30, 2014. ... Siglos XIX y XX (in Spanish) (Seventh ed.). LOM Ediciones. ISBN 978-956-282-232-9. Bengoa, José (2003). Historia de los ... "Law n° 19 253 Indigenous Law" (PDF). Archived from the original (PDF) on 2008-10-30. Retrieved 2013-09-25. "Portal de Registro ...
The bioartificial liver helped an 18-year-old southern California woman survive without her own liver for 14 hours until she ... of antibodies to supermacroporous cryogel adsorbents with immobilized protein A for removal of anthrax toxin protective antigen ... Sussman, NL; Gislason, GT; Conlin, CA; Kelly, JH (May 1994). "The Hepatix extracorporeal liver assist device: initial clinical ... 41 (1): 19-22. doi:10.1002/hep.20562. PMID 15690476. Sauer IM, Goetz M, Steffen I, et al. (May 2004). "In vitro comparison of ...
Antigen receptors on CTL can bind to a 9-10 amino acid chain that is presented by the major histocompatibility complex (MHC) as ... Armanios M, Chen JL, Chang YP, Brodsky RA, Hawkins A, Griffin CA, Eshleman JR, Cohen AR, Chakravarti A, Hamosh A, Greider CW ( ... Humans have two major antigen identifying lymphocytes: CD8+ cytotoxic T-lymphocytes (CTL) and CD4+ helper T-lymphocytes that ... Patel KP, Vonderheide RH (June 2004). "Telomerase as a tumor-associated antigen for cancer immunotherapy". Cytotechnology. 45 ( ...
... carbohydrate antigen 19.9; CEA, carcinoembryonic antigen; FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, oxaliplatin; R0 ... CT, computed tomography; MRI, magnetic resonance imaging; CA 19-9, carbohydrate antigen 19.9; CEA, carcinoembryonic antigen; ... CT, computed tomography; MRI, magnetic resonance imaging; CA 19-9, ... In Memoriam: Healthcare Workers Who Have Died of COVID-19 * Detection and Management of Pediatric Conditions That may Affect ...
CA 19-9 is a serum tumor marker that is often elevated in pancreatic malignancies and might have a role in assessing response ... Carcinoma of the ampulla of Vater: expression of cancer-associated antigens inversely correlated with prognosis. Am J ... Lowe MC, Coban I, Adsay NV, Sarmiento JM, Chu CK, Staley CA, et al. Important prognostic factors in adenocarcinoma of the ...
Carbohydrate Antigen 19-9) in U/mL, kU/L Einheitenumrechner von konventionellen Einheiten in SI-Einheiten ... Umrechnung CA 19-9 (Carbohydrate Antigen 19-9) von / in U/mL, kU/L . Faktoren zur umrechnung von konventionellen Einheiten in ... CA 199 Testwerte sind durch die Verwendung des monoklonalen Antikörpers 1116‐NS‐199 definiert. Gemessen werden 1116‐NS‐199‐ ... Erhöhte CA 199 Testwerte findet man auch bei einer Reihe benigner inklusive entzündlicher Erkrankungen des ...
This test measures the amount of a protein called CA 19-9 in the blood. The test is often used to monitor pancreatic cancer. ... Test ID: CA19: Carbohydrate Antigen 19-9 (CA 19-9), Serum: Clinical and Interpretive; [cited 2022 Aug 11]; [about 2 screens]. ... Cancer Tumor Markers (CA 15-3 [27, 29], CA 19-9, CA-125, and CA-50); 121 p. ... Pancreatic Cancer Action Network [Internet]. Manhattan Beach (CA): Pancreatic Action Network; c2022. CA 19-9; [cited 2022 Aug ...
CONCLUSIONS:There is no doubt that CA 19-9 level is occasionally elevated in patients with obstructive urolithiasis as it was ... The concentration of serum CA 19-9 was 3500 U/mL. Urine cytology provided no signs of abnormality. Intravenous urography ... elevated CA 19-9 has been noted. CASE REPORT:A 58-year-old Caucasian male patient was admitted in our clinic with complaints ... CA 19-9) has been shown to be upregulated in other malignant tumors including gastric, ovarian, hepatocellular, and colorectal ...
Blood serum levels of the antigen CA19-9 are routinely used to monitor PDAC progress,86 87 but have also been suggested as a ... Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg ... The accuracy improved to up to 0.94 AUROC when combined with the less specific carbohydrate antigen (CA) 19-9 serum marker. ... Combination of metagenomic classifiers with antigen CA19-9 levels increases accuracy. ...
i] CEA, carcinoembryonic antigen; CA19-9, carbohydrate atigen; NSE, neuron-specific enolase; ProGRP, progastrin-releasing ... 5S), epithelial membrane antigen (Fig. 5T), cytokeratin AE1/AE3 (Fig. 5U) and Epstein-Barr virus non-coding RNA (Fig. 5V), as ... ZM-0428), epithelial membrane antigen (1:100; cat. no. ZM-0095), cytokeratin AE1/AE3 (1:100; cat. no. ZM-0069) and Epstein-Barr ... human leukocyte antigen DR isotype, immunoglobulin (Ig)M, CD79b and CD20, and weakly expressed CD5 (Fig. 4). The nuclear cells ...
... antigen and cannot produce CA19-9. It has a sensitivity of 80% and specificity of 73% in detecting pancreatic adenocarcinoma, ... CA19-9 (carbohydrate antigen 19.9) is a tumor marker that is frequently elevated in pancreatic cancer. However, it lacks ... CA: A Cancer Journal for Clinicians. 63 (5): 318-48. doi:10.3322/caac.21190. PMC 3769458. PMID 23856911. Vincent A, Herman J, ... See p. 4 for incidence estimates, and p. 19 for survival percentages. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, ...
Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9 ... Our data suggest a breaking of peripheral tolerance to the self-antigen CAP-1 by expansion of antigen-specific CD8+ T cells and ... Exploiting antigen-specific responses to tumor antigens that are shared between different patients and cancer types is one ... Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes ...
including CA 19-9 and carcinoembryonic antigen (CEA). Blood tests can reveal the presence of these tumor markers in some people ... Did the COVID-19 pandemic lead to changes in our personality traits? ...
CA-125 Antigen. B64312/IM2233. 50/100. MUC-1 (CA 15-3). B64314/IM2397. 50/100. ...
... including CA 19-9, CEA (carcinoembryonic antigen), CYFRA 21-1, and NSE (neuron-specific enolase), and for HIV-1 and HIV-2 were ... Helmut J.F. Salzer, Department of Pulmonary Medicine, Kepler University Hospital, Krankenhausstrasse 9, 4021 Linz, Austria ... 9). However, that patient likely did not have NTM-PD because M. hassiacum was isolated in only 1 of 3 sputum samples, he showed ...
CA19-9-carbohydrate antigen 19-9. CBD-common bile duct. CC or CCA-cholangiocarcinoma. CD-Crohns disease. CEA-carcinoembryonic ... antigen. Dx-diagnosis. GGT-gamma-glutamyltranspeptidase. ERCP-endoscopic retrograde cholangiopancreatography. FNA-fine needle ...
Search our range of CA marker antibodies and proteins including CA 125, CA 15-3, CA19-9 and CA72-4. ... CA 125 Antigen Catalog No: J66201 Source: Cell Culture Details: High Pure. ... CA 125 Antigen Catalog No: J66202 Source: Cell Culture Details: Part Pure. ... CA markers Products. CA markers are biomarkers found in blood, urine, or body tissues that can be elevated by the presence of ...
Cancer Antigen CA 125. Cancer Antigen CA 15-3. Cancer Antigen CA 19-9 ... CBC, CEA, CA 15-3, CA 125, CA 19-9, CA 27.29, AFP ... Carcinoembryonic Antigen (CEA): CEA is a tumor marker that is ... Carcinoembryonic Antigen (CEA): CEA is a tumor marker that is often elevated in people with various types of cancer including, ... Carcinoembryonic Antigen (CEA): CEA is a tumor marker that is often elevated in people with various types of cancer including, ...
Cancer Antigen 125 (CA-125) is a biomarker for ovarian cancer with low sensitivity and specificity. High levels of CA-125 can ... Cancer Antigen 15-3 (CA15-3): It is used in diagnosis and prognosis of breast cancer. Its sensitivity for the diagnosis of ... Cancer Antigen 19-9 (CA 19-9): It is diagnostic and prognostic marker for pancreatic cancer and bladder cancer. Its level is ... Prostate Specific Antigen (PSA): It is diagnostic and prognostic marker of prostate cancer. PSA is not very effective for ...
Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are the most widely used biomarkers in clinical practices ... CA Cancer J Clin. 2020;70:7-30.. * Cited Here , *PubMed , CrossRef , ... Without anoikis resistance, cancer cells will not survive after they detached from their primary site.[7,9] Recent researches ... 19]. Shen Y, Yang J, Xu Z, et al. Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer ...
Normal alpha-fetoprotein, CA 19-9, and carcinogenic embryonic antigen (CEA) levels bolster the clinical suspicion of a benign ...
Background: Carbohydrate antigen (CA) 19-9 producing splenic cysts are relatively rare, and usually occur in females and in ... The patients serum CA19-9 level decreased from 3,437 to 62 U/ml after surgery, and she has remained well with no recurrence ... Thoracentesis revealed its CA19-9 level was over 600,000 U/ml; cytologic examination was negative for malignancy. Although ... We diagnosed the patient with CA19-9 producing splenic cysts and performed laparoscopic decapsulation. ...
Carcinoembryonic antigen), CA-125, etc. All tests, including the prior imaging run by GP and GI specialist that the GP referred ... Thorough lab investigations ordered, including amylase, LFTs, KFTs, CA 19-9, CEA ( ... www.thehelpfoundation.ca). He is licensed in both British Columbia and Arizona. He serves as co-chair of the Advisory Committee ...
The Sialyl Lewis A antigen, or CA 19-9, is the prototype serum biomarker for adenocarcinoma of the pancreas. Regardless of in ... The GCTM-5 antigen advanced may be detected within the sera of sufferers with pancreatic adenocarcinoma. The GCTM-5 epitope ... We report the biochemistry and tissue expression of the GCTM-5 antigen, a pancreatic most cancers marker associated to, however ... Antibodies to a CA 19-9 Associated Antigen Advanced Establish SOX9 Expressing Progenitor Cells In Human Foetal Pancreas and ...
CA 19-9: cancer antigen 19-9 is sometimes produced by pancreatic, bile duct and gall bladder cancers ... COVID-19 Pfizer Vaccine events for children under 5 , COVID-19 Novavax Vaccine now available ...
BACKGROUND/AIMS: Elevated carbohydrate antigen (CA) 19-9 level may be unable to differentiate between benign and malignant ... Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary ... 19. Endoscopic ultrasound-guided biliary drainage: Complications and their management Isayama H, Nakai Y, Yamamoto N, Matsubara ... 9. Clinical Outcomes of Bilateral Stent-in-Stent Placement Using Self-Expandable Metallic Stent for High-Grade Malignant Hilar ...
Serum carbohydrate antigen 19-9 (CA19-9) is mainly used for the diagnosis and prognostic assessment of pancreatobiliary ... Can CA 19-9 be elevated for no reason?. If you do not have cancer and your results show a higher than normal level of CA 19-9, ... How reliable is CA 19-9?. Overall, an elevated serum CA 19-9 level has a sensitivity of 79-81% and a specificity of 82-90% for ... What is the half life of CA 19-9?. The average half-life of CA 19-9 was 0.5 days in the first compartment and 4.3 days in the ...
Laboratory examinations, including routine blood tests, liver function tests, as well as serum carbohydrate antigen (CA) 19-9 ... 2002 Jun 29;359(9325):2224-9. PubMed PMID: 12103285.. *Aghayan DL, Kazaryan AM, Dagenborg VJ, et al. Long-Term Oncologic ... 9). Yoon et al. reported favorable long-term oncologic results of laparoscopic radical cholecystectomy by including 2 cases of ...
Blood tests to detect tumor markers, including carcinoembryonic antigen (CEA) and CA 19-9, may help your physician follow you ... Carcinoembryonic Antigen. *Carcinoembryonic antigen: Carcinoembryonic antigen (CEA) is a protein found in many types of cells ... Carcinoembryonic antigen (CEA) is a cancer marker. (Web site). Tumors. *These tumors often produce carcinoembryonic antigen ( ... CARCINOEMBRYONIC ANTIGEN. PROGNOSTIC VALUE. TREATMENT. RECURRENCE. COLON. CERTAIN CANCERS. MEDULLARY. CALCITONIN. PATIENTS. ...
Carcinoembryonic antigen (CEA) assay Imaging studies. Ultrasonography (US) is a standard initial study in patients with right ... CA 19-9 assay * ... 9] may contribute to gallbladder cancer through its association ...
... whereas tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and neuron-specific enolase ( ... R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015," CA: Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5- ... and epithelial membrane antigen contributes to the definitive diagnosis of a primary lesion in pancreatic metastasis [32]. ... Conversely, pancreatic metastasis of RCC is detected without any symptoms in up to 50% of cases [19]. In the present case, ...
We do not ship to New York addresses. ...
Do not use the tumor markers carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9) in blood or cyst fluid to ...

No FAQ available that match "ca 19 9 antigen"